prostate cancerCELL-FREE DNAPOLY(ADP-RIBOSE) POLYMERASEHOMOLOGOUS RECOMBINATIONSYNTHETIC LETHALITYREVERSION MUTATIONSREPAIRIn May 2020, the poly(ADP-ribose) polymerase (PARP) inhibitors rucaparib and olaparib were Food and Drug Administration approved for the management of metastatic castration-resistant ...
[2] Omalley D M. New therapies for ovarian cancer ll . Journal of the National Comprehensive Cancer Network : JNCCN,2019,17 (55) : 619-621. [3] Mateo J, Lord C J, Serra V, et al. A decade of clinical development of PARP inhibitors in perspective [j] . Annals of Oncology: Offici...
原文阅读：https://www.urotoday.com/conference-highlights/eau-2024/eau-2024-prostate-cancer/151067-eau-2024-parp-inhibitors-only-for-patients-with-alterations-in-dna-repair-genes-no.html
Role of biomarkers in the development of PARP inhibitors. Biomark Cancer. 2016;8(Suppl 1):15–25. doi:10.4137/BIC.S36679. Article PubMed PubMed Central Google Scholar Rafii S GC, Ang JE, Kumar R, et al.. (2015) What clinical factors influence advanced BRCA1/2 mutant ovarian cancer ...
[18] Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT01576172. [19] Lord CJ, Ash...
merase inhibitor( PARPi ) can inhibit DNA repair mediates the death of tumor cells with such gene mutations. Since PARP inhibitors were first approved for advanced ovarian cancer in 2014, r esearch on DNA damage repair gene muta tions and ...
(NMPA)forthetreatmentofprostatecancer.Atpresent,consensusonthepreventionand management ofadverseeventofPARPinhibitorsinprostatecancerhasyetnotbeenestablishedinChina.Therefore,theexpert groupoftheChineseUrologicalDoctorAssociation (CUDA)formulatedthe"ChineseExpertConsensusonPre- ventionand ManagementofAdverseEffectsDuring...
PARP (poly ADP-ribose polymerase) inhibitors have recently emerged as a new treatment option for metastatic castration-resistant prostate cancer (mCRPC) with a poor prognosis and are expected to contribute significantly to improving survival rates.Howeve
Part 1: Oliver Sartor, MD, gives an overview of the use of PARP inhibitors to treat metastatic castration-resistant prostate cancer. Part 2: Alicia Morgans, MD, MPH, discuses the importance of PARP inhibitors in the treatment of metastatic prostate canc
Assess homologous recombination repair mutations and BRCA mutations to meet the currently approved use of PARP inhibitors for the treatment of prostate cancer Plan PARP inhibitor–based combination therapy for patients with advanced prostate cancer, considering HRRm and BRCAm status, recent guideline update...